Bao Pharma Reports No Share Capital Changes in May 2026, Maintains Public Float Compliance

Bulletin Express06-01

Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) submitted its Monthly Return to the Hong Kong Stock Exchange for the period ended 31 May 2026, confirming that no adjustments occurred in either authorised or issued share capital during the month.

Authorised/Registered Share Capital • Ordinary H shares: 154.33 million shares at RMB 0.20 par value, representing RMB 30.87 million. • Ordinary domestic shares: 171.65 million shares at RMB 0.20 par value, representing RMB 34.33 million. Total authorised share capital remained unchanged at RMB 65.20 million.

Issued Shares • H shares outstanding: 154.33 million (no treasury shares). • Domestic shares outstanding: 171.65 million. Combined issued share count stands at 325.98 million shares, identical to the prior month.

Public Float The company affirmed compliance with the Main Board Rule 13.32D(1) requirement that at least 25% of its H-share class be held by the public.

Corporate Actions The filing notes no activity in share options, warrants, convertible securities, treasury shares, or other share-issuance arrangements during May 2026.

The report was authorised by Executive Director Liu Yanjun and submitted on 01 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1113124555?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 17:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113124555","market":"us","top_or_hot":-1,"title":"Bao Pharma Reports No Share Capital Changes in May 2026, Maintains Public Float Compliance","media":"Bulletin Express","content":"<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) submitted its Monthly Return to the Hong Kong Stock Exchange for the period ended 31 May 2026, confirming that no adjustments occurred in either authorised or issued share capital during the month.</p>\n<p>Authorised/Registered Share Capital  \n• Ordinary H shares: 154.33 million shares at RMB 0.20 par value, representing RMB 30.87 million.  \n• Ordinary domestic shares: 171.65 million shares at RMB 0.20 par value, representing RMB 34.33 million.  \nTotal authorised share capital remained unchanged at RMB 65.20 million.</p>\n<p>Issued Shares  \n• H shares outstanding: 154.33 million (no treasury shares).  \n• Domestic shares outstanding: 171.65 million.  \nCombined issued share count stands at 325.98 million shares, identical to the prior month.</p>\n<p>Public Float  \nThe company affirmed compliance with the Main Board Rule 13.32D(1) requirement that at least 25% of its H-share class be held by the public.</p>\n<p>Corporate Actions  \nThe filing notes no activity in share options, warrants, convertible securities, treasury shares, or other share-issuance arrangements during May 2026.</p>\n<p>The report was authorised by Executive Director Liu Yanjun and submitted on 01 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bao Pharma Reports No Share Capital Changes in May 2026, Maintains Public Float Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBao Pharma Reports No Share Capital Changes in May 2026, Maintains Public Float Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-01 17:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) submitted its Monthly Return to the Hong Kong Stock Exchange for the period ended 31 May 2026, confirming that no adjustments occurred in either authorised or issued share capital during the month.</p>\n<p>Authorised/Registered Share Capital  \n• Ordinary H shares: 154.33 million shares at RMB 0.20 par value, representing RMB 30.87 million.  \n• Ordinary domestic shares: 171.65 million shares at RMB 0.20 par value, representing RMB 34.33 million.  \nTotal authorised share capital remained unchanged at RMB 65.20 million.</p>\n<p>Issued Shares  \n• H shares outstanding: 154.33 million (no treasury shares).  \n• Domestic shares outstanding: 171.65 million.  \nCombined issued share count stands at 325.98 million shares, identical to the prior month.</p>\n<p>Public Float  \nThe company affirmed compliance with the Main Board Rule 13.32D(1) requirement that at least 25% of its H-share class be held by the public.</p>\n<p>Corporate Actions  \nThe filing notes no activity in share options, warrants, convertible securities, treasury shares, or other share-issuance arrangements during May 2026.</p>\n<p>The report was authorised by Executive Director Liu Yanjun and submitted on 01 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1113124555","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113124555","pubTimestamp":1780304730,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) submitted its Monthly Return to the Hong Kong Stock Exchange for the period ended 31 May 2026, confirming that no adjustments occurred in either...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"宝药业报告2026年5月股本无变动，维持公众持股量合规","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) submitted its Monthly Return to the Hong Kong Stock Exchange for the period ended 31 May 2026, confirming that no adjustments occurred in either authorised or issued share capital during the month.\nAuthorised/Registered Share Capital  \n• Ordinary H shares: 154.33 million shares at RMB 0.20 par value, representing RMB 30.87 million.  \n• Ordinary domestic shares: 171.65 million shares at RMB 0.20 par value, representing RMB 34.33 million.  \nTotal authorised share capital remained unchanged at RMB 65.20 million.\nIssued Shares  \n• H shares outstanding: 154.33 million (no treasury shares).  \n• Domestic shares outstanding: 171.65 million.  \nCombined issued share count stands at 325.98 million shares, identical to the prior month.\nPublic Float  \nThe company affirmed compliance with the Main Board Rule 13.32D(1) requirement that at least 25% of its H-share class be held by the public.\nCorporate Actions  \nThe filing notes no activity in share options, warrants, convertible securities, treasury shares, or other share-issuance arrangements during May 2026.\nThe report was authorised by Executive Director Liu Yanjun and submitted on 01 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1113124555","isCrawlerRequest":true}